Join to access to all OVN content. Join for Free
The Gamification of MSL Metrics
Gamifying MSL Metrics Medical Affairs Innovation MSL Performance Evaluation High-Impact Activities MSL Success Strategies

The Gamification of MSL Metrics


Share This Article


Summary

In this episode, Bart Brown joins Tom Caravela to explore the concept of gamifying MSL metrics. Bart shares his innovative point system designed to evaluate MSL performance beyond traditional metrics. They delve into the challenges of current evaluation methods and discuss how this new system emphasizes high-impact activities and diverse success strategies. Bart provides insights on implementing these strategies and addresses potential downsides. The conversation highlights the importance of showcasing value in Medical Affairs. The episode wraps up with a call for listener feedback and suggestions for future topics.

My guest this week is Bart Brown, Medical Affairs Leader who shares his interesting concept on how to gamify MSL metrics and KPIs.

Bart shares….

👉 How are MSLs currently evaluated and what is the standard
👉 A unique way to “gamify” MSL metrics and KPIs
👉 How this unique system can be implemented and why
👉 What the benefits would be to this system
👉 What advice he has for MSL success in 2024

Click for Source
Gamifying MSL Metrics, Medical Affairs Innovation, MSL Performance Evaluation, High-Impact Activities, MSL Success Strategies

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN